# 1 This is a sample peer review report : a prospective observational study

2 This is a sample peer review report.

3

## 4 Abstract

5 Snakebite related acute kidney injury (AKI) is a common community-acquired AKI in tropical countries leading to death and disability particularly in young earning adults of families. 6 7 However, there were limited data on factors associated with snake related AKI in Southeast Asia. Therefore, a prospective observational study was conducted in the three tertiary hospitals 8 between 2015 and 2016 among adults with snake envenomation with the aims to determine 9 10 renal manifestations and to evaluate factors associated with snakebite related AKI. Patient data including baseline characteristics, clinical parameters, laboratory findings, hospital management 11 and outcomes were recorded in a case report form and compiled data for analysis. Of 258 adults 12 13 with snake envenomation, common renal manifestations included reduce urine volume (128/258 14 patients, 49.6%), renal tenderness (114/258 patients, 44.2%) and gross hematuria (46/258 patients, 17.8%). Abnormal urine findings included urine protein to creatinine ratio ≥1 (112/186 15 16 patients, 60.2%), microscopic hematuria (81/255 patients, 31.4%) and pigmenturia (38/255 17 patients, 14.7%). Electrolyte abnormalities included hyponatremia (115/258 patients, 44.6%), hypocalcemia (88/256 patients, 34.4%), hyperphosphatemia (68/256 patients, 26.6%) and 18 hypokalemia (52/258 patients, 20.2%). AKI was observed in 140 (54.3%) patients and the 19 20 majority of the patients were AKI stage III (110 patients, 78.6%). Using multivariate logistic regression analysis, the factors that independently associated with AKI included snakebites of 21 22 Viperidae family or had clinical syndrome of Viperidae (odds ratio [OR]: 12.93, 95% confidence

**Commented [A1]:** Please find the suggested title below. If you agree with the suggestion, please revise the present title accordingly.

Clinical and laboratory parameters associated with acute this is a sample peer review report: A prospective observational study

### Commented [A2]: Dear Authors,

Thank you for the opportunity to assist you with your manuscript. After reviewing your work I have made some comments to further enhance your paper. Please review and revise, if you agree. Regarding the main sections, kindly note as follows: <u>Introduction</u>: I have suggested some modifications to enhance the clarity of your background and rationale. <u>Methods</u>: This was generally well presented. <u>Results</u>: Please indicate where all your results are to be found, or if they were not shown. Otherwise, it is difficult for the reader to

they were not shown. Otherwise, it is difficult for the reader to follow your results.

Discussion: I have made a few suggestions to enhance clarity. Also ensure all citations are included.

Please also see further comments below

The manuscript is overall well written, but too long. The general length of the manuscript for original research considered by majority of the journals are 2500-4500 words. Hence significant reduction of words (minimum 4000 words) is necessary. In order to achieve this, authors may provide some of the data and clinical information (methodology section) in table format.

In addition, please avoid providing same data both in text and table Providing data only in table, where relevant, will help to minimize the word count of the text.

### Commented [A3]: Please provide the month here.

**Commented [A4]:** Please mention if you mean 'factors associated at the time of or during hospitalization'.

**Commented [A5]:** We recommend that you delete the descriptive analysis of the study from the abstract.

Page 1 of 4

- 23 intervals [CI]: 3.37–49.61; *p* <0.001), presence of hypotension (OR: 3.59; 95% CI: 1.31–9.86; *p*
- 24 = 0.013), WBC >10 ×10<sup>3</sup> cells/ $\mu$ L (OR: 3.41, 95% CI: 1.43–8.15; *p* = 0.006), overt DIC (OR:
- 25 2.36, 95% CI: 1.15–4.83; *p* = 0.019), serum creatine kinase ≥800 IU/L (OR: 3.86, 95% CI: 1.62–
- 26 9.20; p = 0.002), presence of microscopic hematuria (OR: 3.31, 95% CI: 1.40–7.80; p = 0.006)
- and duration from bite to needle  $\geq 2$  h (OR: 3.48, 95% CI: 1.52–7.94; p = 0.003). This findings
- 28 information might help clinicians identify snakebite patients who are at risk of AKI and to
- 29 provide proper\_clinical management. -for patients who are at risks for snake related AKI and
- 30 might reduce the incidence of community acquired AKI in tropical countries.
- 31 Key words: Factors associated; Multivariate analysis; Snake<u>bite</u> related AKI; Prospective study

**Commented [A6]:** Please clarify what this term means.

**Commented [A7]:** I have some minor edits. Please check if you agree with the edits.

Page <u>2 of</u> 4

## 32 Introduction

33	Currently, community-acquired acute kidney injury (AKI) is a major public health
34	problem in tropical countries particularly in Asia [1,2]. Community-acquired AKI in tropical
35	countries are related to young individuals with (mean age of 37-47 years) whose do not have pre-
36	existing comorbidities [2]. These patients are at risk for the development of chronic kidney
37	disease [3]. The community-acquired AKI in tropical countries is usually caused by any single
38	etiology including tropical infections, environmental exposure to toxin or occupational hazard to
39	snakebite envenomation [1,2]. It was reported that the highest burden of snakebite envenomation
40	was observed in South Asia, Southeast Asia and sub-Saharan Africa [4]. In Southeast Asia,
41	envenomation by two families of venomous snakes including Elapidae and Viperidae showed a
42	significant morbidity and mortality with the case fatality rate of 0.4-20.0% [5,6]. Following
43	snakebite envenomation by snakes of the family Elapidae, Viperidae and Colubridae, patients
44	could develop renal manifestations including proteinuria, hematuria, pigmenturia and AKI [7,8].
45	Snakebite related AKI was reported ranging from 8.0-43.0% of patients with snakebite
46	envenomation [9-15], of which renal replacement therapy (RRT) was required in approximately
47	15.0-55.0% [9-11, 13] and the case fatality rate occurred in 8.0-39.0% [9-11, 13,14]. Previous
48	reports from Brazil showed the more susceptibility of snakebite related AKI with age increasing
49	[16,17]. However, the factors associated with the snakebite related $AKI \le AKI$ included age <12
50	years, time from hospitalization to antivenom treatment $>2$ h, time from bite to needle $>2$ h,
51	longer time from bite to hospital, cellulitis, regional lymphadenopathy, hypotension, higher total
52	bilirubin level, lower hemoglobin level, intravascular hemolysis, prolong 20-minute whole blood
53	clotting test (20WBCT), prolong bleeding time, prolong prothrombin time (PT), hemorrhagic

**Commented [A8]:** The mean age cannot be a range, as stated, please include either mean age (one point estimate) or range.

**Commented [A9]:** Authors, please make it clear to readers if Snakebite related AKI(sAKI) is different from community-acquired AKI(cAKI) or if the former is a subclass of the later. Also consider using the abbreviations consistently

**Commented [A10]:** Do you want to mean with increasing age? Please clarify

**Commented [A11]:** Please clarify what the term "time from bite to needle" means as the meaning is not clear.

<u>Page 3 of 4</u>

manifestations, serum creatine kinase >2000 IU/L, dark or brown urine color, albuminuria and
longer length of hospitalization [9,10,12,13,15].

Recently, a report showed that there were approximately 10,000 cases of snakebite 56 occuring annuallyRussell's viper was the most common snakebite envenomation which accounted 57 58 in for 90% of for snakebite cases with the case fatality rate of 10.4% [18]. Previous report showed that approximately 42% of patients with Russell's viper bites (10 out of 24 patients) developed 59 snakebite related AKI, all these cases recovered after antivenom treatment, but the other 21% of 60 the snakebite patients (5 out of 24 patients) developed snakebite related AKI following antivenom 61 treatment [19]. However, there were limited data on the renal manifestations and the factors 62 associated with the development of snakebite related AKI. Previous studies showed that the 63 64 factors associated with the snakebite related AKI sAKI varied among studies due to differences in study population, the potency and composition of snake venom which is different in geographic 65 region of study sites, accessibility of management facilities and study design. 66

Therefore, a prospective observational study was conducted in the three tertiary hospitals between 2015 and 2016 among patients with snakebite envenomation with the aims (1) to determine renal manifestations and (2) to determine the factors associated with the development of snakebite related AKI. This information might help clinicians in identifying patients who might develop renal involvement after snakebite envenomation and who are at risk for the occurrence of snakebite related AKI in order to provide the proper management for decreasing the incidence of community-acquired AKI in tropical countries. **Commented [A12]:** Please make it clear which previous studies and cite them appropriately.

Commented [A13]: Provide month along with the year to be more precise about the information on data collection Commented [A14]: Do you mean independent clinical factors?

**Commented [A15]:** AKI at the time of hospital admission or during hospitalization? Please confirm.

Page 4 of 4